TidalHealth study brings awareness to a new promising COVID-19 treatment

SALISBURY, Md.- A promising new COVID-19 treatment could be seen in the future-and TidalHealth is playing a role in it.

TidalHealth’s Richard A. Henson Research Institute worked with Partner Therapeutics for a clinical trial of a new treatment for the virus.

The study was done over a 4 month period starting in 2020 and ending this year.

A drug called  Leukine was given to some patients enrolled.

Researchers said the drug has the potential to limit the damage of lung cells and restore normal function of the damaged parts.

The exciting part is that researchers said preliminary results are looking promising and could be a game changer for COVID-19 patients in our community.

“It looks like it might have a potential role and it was very safe and very well tolerated,” Dr. Robert Chasse, Physician and Medical Director of the ICU, said. “In, this particular instance it met its primary end point in what it looked like it improved the ability of the lung to do what it needs to do which is gas exchange.”

There were 49 patients enrolled in the study.

We’re told the drug was delivered through inhalation and has actually been around for 30 years.

Over the last three decades the drug has been used mostly in cancer treatments and bone marrow transplants.

Since, the study is done next steps would be up to Partner Therapeutics.

They can choose to bring the information to the FDA.